Prot#CIN-107-122 : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of CIN-107 for the Treatment of Patients With Primary Aldosteronism (PA)

Project: Research project

Project Details

StatusActive
Effective start/end date2/9/22 → 2/9/25

Funding

  • Medpace Clinical Research LLC (Prot#CIN-107-122 Amnd 3 // Prot#CIN-107-122 Amnd 3)
  • AstraZeneca PLC (Prot#CIN-107-122 Amnd 3 // Prot#CIN-107-122 Amnd 3)